1,101 posts by 291 firms and lawyers
Cannabis law explained by the lawyers who practise it: analysis and commentary from law firms around the world, with the Cannabis Law Journal.
Cannabis companies are used to hearing “no” from the tax system, so a recent ruling from the Colorado Department of Revenue stands out. In Private Letter Ruling 26-005, issued in July 2026, the Department considered whether a…
Since the April 2026 filing season, the landscape surrounding Section 280E of the Internal Revenue Code has continued to evolve in significant ways. , d/b/a Ultra Health v.
https://www.jdsupra.com/legalnews/virginia-retail-cannabis-law-hb-30-faqs-1028661/
On April 23, 2026, the Department of Justice and the Drug Enforcement Administration issued an order moving medical marijuana subject to a state license from Schedule I to Schedule III of the Controlled Substances Act.
Rescheduling did not just change tax treatment and licensing options for cannabis operators. It also changed the assumptions baked into thousands of existing cannabis contracts.
Congress finally has a serious bipartisan alternative to the federal hemp ban scheduled to take effect this November.
On April 23, 2026, the DOJ and DEA issued a final order rescheduling certain marijuana products from Schedule I to Schedule III of the Controlled Substances Act. The order is subject to litigation, but it remains in effect for…
This is the second installment in a series on what 1,446 pages of FOIA-ed IRS cannabis training materials reveal. ” This one is about something the IRS places too much faith in: your cannabis business’s METRC data.
After years of delays and political wrangling, the federal government’s long-awaited hearing on whether to move marijuana from Schedule I to Schedule III of the Controlled Substances Act is finally underway. On Jun. 29th, the DEA…
The Drug Enforcement Administration is scheduled to hold a historic hearing beginning Monday, June 29, 2026, which could extend Schedule III cannabis rescheduling to adult-use marijuana and reshape the federal regulatory…
Massachusetts’ legal cannabis market is undergoing a transformation, with new rules that increase the amount of marijuana someone over 21 can purchase, ensure potency levels and restructure the Cannabis Control Commission, among…
Article by: Ivy Perez-Bader, Raza Lawrence, Jana Weltzin, Greg Cowan, and Tom Zuber
The federal regulatory landscape governing cannabis in the United States is undergoing its most significant transformation in over fifty years.
Marijuana’s proposed move from Schedule I to Schedule III under the Controlled Substances Act has renewed focus on what rescheduling could mean for marijuana-related businesses (MRBs) and the financial institutions that serve…
The week of April 18 through April 23, 2026 produced two distinct and legally consequential federal actions on controlled substances. On April 18, President Trump signed Executive Order 14401, directing the federal government to…
Today, April 23, 2026, the United States Acting Attorney General, Todd Blanche, (the “AG”) and the U.S. Department of Justice (“DOJ”) announced the issuance of a final order that “immediately places” some cannabis into Schedule…
On April 23, 2026, the Department of Justice (DOJ) and the Drug Enforcement Administration (DEA) took a historic step the cannabis industry has awaited for years: Acting Attorney General Todd Blanche signed a final rule…
The rescheduling of certain cannabis products to Schedule III represents a meaningful shift in federal cannabis policy and offers long-awaited tax relief for portions of the industry.
On April 23, 2026, as we discussed in our prior client alert, the Department of Justice issued a Final Order immediately placing cannabis “subject to a state medical marijuana license” in Schedule III of the Controlled Substances…
S. S. Food and Drug Administration (FDA)-approved products containing marijuana and marijuana products regulated by a state medical marijuana license in Schedule III of the Controlled Substances Act (CSA).